[1]
|
Arnold, S., Gur, R., Shapiro, R., et al., (1995) Prospective clinicopathologic studies of schizophrenia: Accrual and assessment of patients. American Journal of Psychiatry, 152, 731-737.
|
[2]
|
Raina, P., Santaguida, P., Ismaila, A., et al. (2008) Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Annals of Internal Medicine, 148, 379-397.
doi:10.7326/0003-4819-148-5-200803040-00009
|
[3]
|
Aleman, A., Hijiman, R., De Haa, E.H.F., et al. (1999) Memory impairment in schizophrenia: A meta-analysis. American Journal of Psychiatry, 156, 1358-1366.
|
[4]
|
Heinrichs, R.W. and Zakzanis, K.K. (1998) Neurocognitive deficits in schizophrenia: A quantitative review of the evidence. Neuropsychology, 12, 426-445.
doi:10.1037/0894-4105.12.3.426
|
[5]
|
Bokat, C.E. and Goldberg, T.E. (2003) Letter and category fluency in schizophrenic patients: A meta-analysis. Schizophrenia Research, 64, 73-78.
doi:10.1016/S0920-9964(02)00282-7
|
[6]
|
Lenzi, A. and Tuscano, D. (2004) Do acetylcholinesterase inhibitors have a role in improving cognitive impairment in patients with schizophrenia. International Journal of Pharmacological Medicine, 18, 139-148.
doi:10.2165/00124363-200418030-00002
|
[7]
|
Ribeiz, S., Bassitt, D., Arrais, J., et al. (2010) Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: A systematic review and meta-analysis of the literature. CNS Drugs, 24, 303-317. doi:10.2165/11530260-000000000-00000
|
[8]
|
Djordjevic, S., Japalak, S. and Vodojevic, V. (2010) Effect of rivastigmine tartarat in therapy of patients with schizophrenia. Annals of General Psychiatry, 9, S91.
|
[9]
|
Stryjer, R., Bar, F., Strous, R., et al. (2002) Donepezil management of schizophrenia associated with dementia. Journal of Clinical Psychopharmacology, 22, 226-229.
doi:10.1097/00004714-200204000-00021
|
[10]
|
D. Mazeh, H. Zemishlani, Y. Braka, et al. (2006) Donepezil for the negative signs in elderly patients with schizophrenia: An add-on, double blind, crossover, placebo-controlled study. International Journal of Psychogeriatrics, 18, 429-436.
doi:10.1017/S1041610205003017
|
[11]
|
Stryjer, R., Strous, R., Bar, F., et al. (2003) Beneficial effects of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clinical Neuropharmacology, 26, 12-17.
doi:10.1097/00002826-200301000-00004
|
[12]
|
Mendelsohn, E., Rosenthal, M., Bohiri, Y., et al. (2004) Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: An open-label study investigating effects on cognition, behaviour and activities of daily living. International Journal of Clinical Pharmacology, 19, 319-324.
|